TISIDB

Summary
Symbol	UIMC1
Name	ubiquitin interaction motif containing 1
Aliases	RAP80; receptor associated protein 80; X2HRIP110; receptor-associated protein 80; retinoid X receptor-intera ......
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Note=Localizes at sites of DNA damage at double-strand breaks (DSBs).
Domain	-
Function	Ubiquitin-binding protein (PubMed:24627472). Specifically recognizes and binds 'Lys-63'-linked ubiquitin (PubMed:19328070, Ref.37). Plays a central role in the BRCA1-A complex by specifically binding 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX. Also weakly binds monoubiquitin but with much less affinity than 'Lys-63'-linked ubiquitin. May interact with monoubiquitinated histones H2A and H2B; the relevance of such results is however unclear in vivo. Does not bind Lys-48'-linked ubiquitin. May indirectly act as a transcriptional repressor by inhibiting the interaction of NR6A1 with the corepressor NCOR1.

> Gene Ontology [ TOP ]
Biological Process	GO:0000075 cell cycle checkpoint GO:0000077 DNA damage checkpoint GO:0000726 non-recombinational repair GO:0006282 regulation of DNA repair GO:0006302 double-strand break repair GO:0006303 double-strand break repair via nonhomologous end joining GO:0009314 response to radiation GO:0010212 response to ionizing radiation GO:0016570 histone modification GO:0016578 histone deubiquitination GO:0016579 protein deubiquitination GO:0031570 DNA integrity checkpoint GO:0031572 G2 DNA damage checkpoint GO:0045739 positive regulation of DNA repair GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0070536 protein K63-linked deubiquitination GO:0070537 histone H2A K63-linked deubiquitination GO:0070646 protein modification by small protein removal GO:2001020 regulation of response to DNA damage stimulus GO:2001022 positive regulation of response to DNA damage stimulus
Molecular Function	GO:0031593 polyubiquitin binding GO:0032182 ubiquitin-like protein binding GO:0042393 histone binding GO:0043130 ubiquitin binding GO:0070530 K63-linked polyubiquitin binding
Cellular Component	GO:0070531 BRCA1-A complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03440 Homologous recombination
Reactome	R-HSA-1640170: Cell Cycle R-HSA-69620: Cell Cycle Checkpoints R-HSA-5693606: DNA Double Strand Break Response R-HSA-5693532: DNA Double-Strand Break Repair R-HSA-73894: DNA Repair R-HSA-5688426: Deubiquitination R-HSA-69481: G2/M Checkpoints R-HSA-69473: G2/M DNA damage checkpoint R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA) R-HSA-5693538: Homology Directed Repair R-HSA-392499: Metabolism of proteins R-HSA-5689901: Metalloprotease DUBs R-HSA-5693571: Nonhomologous End-Joining (NHEJ) R-HSA-597592: Post-translational protein modification R-HSA-5693607: Processing of DNA double-strand break ends R-HSA-5693565: Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa03440 Homologous recombination

Reactome

R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-5693606: DNA Double Strand Break Response
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-5688426: Deubiquitination
R-HSA-69481: G2/M Checkpoints
R-HSA-69473: G2/M DNA damage checkpoint
R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)
R-HSA-5693538: Homology Directed Repair
R-HSA-392499: Metabolism of proteins
R-HSA-5689901: Metalloprotease DUBs
R-HSA-5693571: Nonhomologous End-Joining (NHEJ)
R-HSA-597592: Post-translational protein modification
R-HSA-5693607: Processing of DNA double-strand break ends
R-HSA-5693565: Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks

Summary
Symbol	UIMC1
Name	ubiquitin interaction motif containing 1
Aliases	RAP80; receptor associated protein 80; X2HRIP110; receptor-associated protein 80; retinoid X receptor-intera ......
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between UIMC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	UIMC1
Name	ubiquitin interaction motif containing 1
Aliases	RAP80; receptor associated protein 80; X2HRIP110; receptor-associated protein 80; retinoid X receptor-intera ......
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of UIMC1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	UIMC1
Name	ubiquitin interaction motif containing 1
Aliases	RAP80; receptor associated protein 80; X2HRIP110; receptor-associated protein 80; retinoid X receptor-intera ......
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of UIMC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.132	0.547
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.312	0.814
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.001	0.999
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.012	0.963
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.186	0.927
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.264	0.92
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.05	0.868
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.007	0.996
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.122	0.93
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.013	0.991
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.31	0.867
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.098	0.038

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of UIMC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	11.1	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	11.1	0.0286
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	UIMC1
Name	ubiquitin interaction motif containing 1
Aliases	RAP80; receptor associated protein 80; X2HRIP110; receptor-associated protein 80; retinoid X receptor-intera ......
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UIMC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	UIMC1
Name	ubiquitin interaction motif containing 1
Aliases	RAP80; receptor associated protein 80; X2HRIP110; receptor-associated protein 80; retinoid X receptor-intera ......
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UIMC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UIMC1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	UIMC1
Name	ubiquitin interaction motif containing 1
Aliases	RAP80; receptor associated protein 80; X2HRIP110; receptor-associated protein 80; retinoid X receptor-intera ......
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UIMC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	UIMC1
Name	ubiquitin interaction motif containing 1
Aliases	RAP80; receptor associated protein 80; X2HRIP110; receptor-associated protein 80; retinoid X receptor-intera ......
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of UIMC1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	UIMC1
Name	ubiquitin interaction motif containing 1
Aliases	RAP80; receptor associated protein 80; X2HRIP110; receptor-associated protein 80; retinoid X receptor-intera ......
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between UIMC1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	UIMC1
Name	ubiquitin interaction motif containing 1
Aliases	RAP80; receptor associated protein 80; X2HRIP110; receptor-associated protein 80; retinoid X receptor-intera ......
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting UIMC1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse UIMC1